BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chan YH, Lee HF, Li PR, Liu JR, Chao TF, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC, Lip GYH. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. Cardiovasc Diabetol 2020;19:63. [PMID: 32404168 DOI: 10.1186/s12933-020-01043-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Alwafi H, Alotaibi B, Naser AY, Salawati E, Qadus S, Sweiss K, Dairi MS, Hassouneh L, Aldalameh Y, Samannodi M. The safety and efficacy of the use of oral anticoagulant medications in patients with diabetes mellitus: A systematic review. Saudi Pharm J 2021;29:1374-82. [PMID: 35002374 DOI: 10.1016/j.jsps.2021.11.001] [Reference Citation Analysis]
2 Rivera-Caravaca JM, Harrison SL, Buckley BJR, Fazio-Eynullayeva E, Underhill P, Marín F, Lip GYH. Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. Cardiovasc Diabetol 2021;20:176. [PMID: 34481513 DOI: 10.1186/s12933-021-01368-6] [Reference Citation Analysis]
3 Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, Ren QW, Tse HF, Cheung BY, Yiu KH. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol 2021;20:100. [PMID: 33962654 DOI: 10.1186/s12933-021-01293-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
4 Ajjan RA, Kietsiriroje N, Badimon L, Vilahur G, Gorog DA, Angiolillo DJ, Russell DA, Rocca B, Storey RF. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J 2021;42:2235-59. [PMID: 33764414 DOI: 10.1093/eurheartj/ehab128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Vaidya AR, Wolska N, Vara D, Mailer RK, Schröder K, Pula G. Diabetes and Thrombosis: A Central Role for Vascular Oxidative Stress. Antioxidants (Basel) 2021;10:706. [PMID: 33946846 DOI: 10.3390/antiox10050706] [Reference Citation Analysis]
6 Cao B, Yao X, Zhang L, Hu X, Chen M, Shen M, Xu L. Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies. Cardiovasc Ther 2021;2021:5520027. [PMID: 34729079 DOI: 10.1155/2021/5520027] [Reference Citation Analysis]
7 Costa OS, O'Donnell B, Vardar B, Abdelgawwad K, Brescia CW, Sood N, Coleman CI. Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis. Curr Med Res Opin 2021;37:1493-500. [PMID: 34166150 DOI: 10.1080/03007995.2021.1947217] [Reference Citation Analysis]
8 Weir MR, Chen YW, He J, Bookhart B, Campbell A, Ashton V. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. Diabetes Ther 2021;12:3167-86. [PMID: 34699020 DOI: 10.1007/s13300-021-01161-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Plitt A, Zelniker TA, Park JG, McGuire DK, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2021;7:f40-9. [PMID: 33063112 DOI: 10.1093/ehjcvp/pvaa120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Kreutz R, Camm AJ, Rossing P. Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. Eur Heart J Suppl 2020;22:O78-86. [PMID: 33380946 DOI: 10.1093/eurheartj/suaa182] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wegeberg AM, Okdahl T, Riahi S, Ejskjaer N, Pociot F, Størling J, Brock B, Brock C. Elevated levels of interleukin-12/23p40 may serve as a potential indicator of dysfunctional heart rate variability in type 2 diabetes. Cardiovasc Diabetol 2022;21:5. [PMID: 34991588 DOI: 10.1186/s12933-021-01437-w] [Reference Citation Analysis]
12 Bertomeu-Gonzalez V, Moreno-Arribas J, Esteve-Pastor MA, Roldán-Rabadán I, Muñiz J, Otero García D, Ruiz-Ortiz M, Cequier Á, Bertomeu-Martínez V, Badimón L, Anguita M, Lip GYH, Marín F; FANTASIIA Study Investigators. Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry. Eur J Clin Invest 2021;51:e13431. [PMID: 33065765 DOI: 10.1111/eci.13431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace 2021;23:1873-91. [PMID: 34411235 DOI: 10.1093/europace/euab184] [Reference Citation Analysis]
14 Coleman CI, Costa OS, Brescia CW, Vardar B, Abdelgawwad K, Sood N. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Cardiovasc Diabetol 2021;20:52. [PMID: 33637082 DOI: 10.1186/s12933-021-01250-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yu D, Zhao Z, Simmons D. Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study. Cardiovasc Diabetol 2020;19:174. [PMID: 33038936 DOI: 10.1186/s12933-020-01152-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]